Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRTS NASDAQ:INAB NASDAQ:LEXX NASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTSGritstone bio$0.03$0.35$0.03▼$3.17$3.50M0.497.01 million shsN/AINABIN8bio$1.39-3.5%$1.52$1.17▼$2.73$14.18M0.2232,253 shs66,215 shsLEXXLexaria Bioscience$0.53-5.2%$0.62$0.46▼$1.55$13.87M0.3458,611 shs16,917 shsQNTMQuantum Biopharma$3.32-3.5%$5.07$2.07▼$31.91$13.13M0.43153,984 shs57,886 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTSGritstone bio0.00%0.00%0.00%0.00%0.00%INABIN8bio-3.47%-1.42%-4.14%-4.14%-33.81%LEXXLexaria Bioscience-5.22%-5.30%-16.75%-44.48%-39.36%QNTMQuantum Biopharma-3.49%-8.29%-22.07%-9.78%-79.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTSGritstone bio$0.03$0.35$0.03▼$3.17$3.50M0.497.01 million shsN/AINABIN8bio$1.39-3.5%$1.52$1.17▼$2.73$14.18M0.2232,253 shs66,215 shsLEXXLexaria Bioscience$0.53-5.2%$0.62$0.46▼$1.55$13.87M0.3458,611 shs16,917 shsQNTMQuantum Biopharma$3.32-3.5%$5.07$2.07▼$31.91$13.13M0.43153,984 shs57,886 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTSGritstone bio0.00%0.00%0.00%0.00%0.00%INABIN8bio-3.47%-1.42%-4.14%-4.14%-33.81%LEXXLexaria Bioscience-5.22%-5.30%-16.75%-44.48%-39.36%QNTMQuantum Biopharma-3.49%-8.29%-22.07%-9.78%-79.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRTSGritstone bio 0.00N/AN/AN/AINABIN8bio 2.00Hold$4.00187.77% UpsideLEXXLexaria Bioscience 2.00Hold$1.50182.86% UpsideQNTMQuantum Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest GRTS, INAB, LEXX, and QNTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026LEXXLexaria Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/4/2026INABIN8bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/28/2026QNTMQuantum Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026QNTMQuantum Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/22/2026LEXXLexaria Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026INABIN8bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRTSGritstone bio$496K7.05N/AN/A$0.54 per share0.06INABIN8bioN/AN/AN/AN/A$2.82 per shareN/ALEXXLexaria Bioscience$710K18.52N/AN/A$0.13 per share4.08QNTMQuantum BiopharmaN/AN/AN/AN/A$1.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRTSGritstone bio-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/AINABIN8bio-$19.44M-$2.61N/AN/AN/AN/A-96.39%-80.18%8/6/2026 (Estimated)LEXXLexaria Bioscience-$11.90M-$0.47N/AN/AN/AN/A-206.02%-162.53%7/13/2026 (Estimated)QNTMQuantum Biopharma-$26.17M-$8.25N/AN/AN/AN/A-941.54%-224.41%8/6/2026 (Estimated)Latest GRTS, INAB, LEXX, and QNTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/13/2026Q3 2026LEXXLexaria Bioscience-$0.06N/AN/AN/A$0.05 millionN/A5/7/2026Q1 2026INABIN8bio-$0.59-$0.26+$0.33-$0.26N/AN/A4/13/2026Q2 2026LEXXLexaria Bioscience-$0.0950-$0.06+$0.0350-$0.06$0.05 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGRTSGritstone bioN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRTSGritstone bio1.832.542.54INABIN8bioN/A10.5010.50LEXXLexaria BioscienceN/A26.8426.84QNTMQuantum BiopharmaN/A0.630.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRTSGritstone bio48.46%INABIN8bio92.05%LEXXLexaria Bioscience13.06%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipGRTSGritstone bio4.61%INABIN8bio14.50%LEXXLexaria Bioscience8.39%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRTSGritstone bio190108.57 million111.84 millionNo DataINABIN8bio209.85 million8.42 millionNot OptionableLEXXLexaria Bioscience724.79 million22.71 millionNot OptionableQNTMQuantum BiopharmaN/A3.82 million3.49 millionN/AGRTS, INAB, LEXX, and QNTM HeadlinesRecent News About These CompaniesQuantum BioPharma Provides Corporate UpdateJuly 7 at 7:00 PM | globenewswire.comCritical Review: Quantum Biopharma (NASDAQ:QNTM) versus Imunon (NASDAQ:IMNN)July 3, 2026 | americanbankingnews.comQuantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive PodcastJuly 2, 2026 | finance.yahoo.comQuantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging StudyJune 29, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging StudyJune 29, 2026 | markets.businessinsider.comNetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple SclerosisJune 26, 2026 | globenewswire.comThe Quest to Repair What Multiple Sclerosis Takes AwayJune 25, 2026 | markets.businessinsider.comQuantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS TherapyJune 25, 2026 | globenewswire.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 TrialsJune 23, 2026 | markets.businessinsider.comQuantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 TrialsJune 23, 2026 | finance.yahoo.comQuantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different ApproachJune 23, 2026 | globenewswire.comQuantum BioPharma (QNTM) Advances Proprietary Therapy for MS TreatmentJune 9, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness MarketsJune 5, 2026 | markets.businessinsider.comQuantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness MarketsJune 5, 2026 | finance.yahoo.comQuantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire PodcastJune 3, 2026 | finance.yahoo.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.June 2, 2026 | globenewswire.comQuantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation CampaignsJune 2, 2026 | globenewswire.comQuantum BioPharma Provides Corporate UpdateJune 1, 2026 | globenewswire.comQuantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging StudyMay 20, 2026 | finance.yahoo.comQuantum BioPharma shares climb as multiple sclerosis imaging study advances (QNTM)May 18, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 High-Yield Stocks With Analyst Support and Room to RunBy Thomas Hughes | June 16, 2026EVs Are Big Winners of the Iran War—Just Not American OnesBy Jessica Mitacek | June 24, 20263 Energy Stocks Built for the AI Power Boom—And BeyondBy Bridget Bennett | June 8, 2026Is Lennar Finally Turning the Corner After Its Housing Slump?By Leo Miller | June 16, 2026KBR Insiders Are Buying While the Market Misreads Its SpinoffBy Thomas Hughes | July 6, 2026GRTS, INAB, LEXX, and QNTM Company DescriptionsGritstone bio NASDAQ:GRTSGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.IN8bio NASDAQ:INAB$1.39 -0.05 (-3.47%) Closing price 07/7/2026 03:59 PM EasternExtended Trading$1.39 0.00 (0.00%) As of 07/7/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. Lexaria Bioscience NASDAQ:LEXX$0.53 -0.03 (-5.22%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$0.53 +0.00 (+0.13%) As of 05:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Quantum Biopharma NASDAQ:QNTM$3.32 -0.12 (-3.49%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$3.20 -0.12 (-3.61%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Apple and Broadcom Forge a Decade-Long Silicon Fortress SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity Palantir's CEO Just Called Out OpenAI and Anthropic Silicon Starvation: Amazon Feasts on Legacy GPUs GE Vernova’s Power Surge Turns the Grid Into an AI Trade 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers Abivax: Wall Street Catches Up to the Data Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
